IDEAYA Biosciences Inc. (NASDAQ: IDYA) — Publicly Traced Asset Review

As of the Oct 30, 2026 close, IDYA traded at ~$31.96 with a market cap of ~$3.1B [11], [12]. IDEAYA is a San Francisco-based, pre-commercial precision medicine oncology company targeting molecularly defined cancers, led by darovasertib (PKC inhibitor in uveal melanoma), plus DLL3 (IDE849) and MTAP-deleted (IDE397/IDE892) programs [11], [18], [20].

Recent Catalysts (roughly July–October 2026)